KBC Group
CRNX icon

KBC Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

KBC Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111K Hold
3,064
– – ﹤0.01% 1260
2025
Q4 		$143K Hold
3,064
– – ﹤0.01% 1066
2025
Q3 		$128K Hold
3,064
– – ﹤0.01% 1117
2025
Q2 		$88K Sell
3,064
-1,018
-25% -$31.4K ﹤0.01% 1279
2025
Q1 		$137K Buy
4,082
+370
+10% +$13.8K ﹤0.01% 1293
2024
Q4 		$190K Buy
3,712
+1,519
+69% +$85K ﹤0.01% 1156
2024
Q3 		$112K Buy
2,193
+407
+23% +$21K ﹤0.01% 1213
2024
Q2 		$80K Hold
1,786
– – ﹤0.01% 1305
2024
Q1 		$84K Buy
+1,786
New +$69.9K ﹤0.01% 1219

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

KBC Group's CRNX Position: Q1 2026 in Review

KBC Group held its Crinetics Pharmaceuticals (CRNX) position steady in Q1 2026 at 3,064 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

KBC Group first reported a position in CRNX in Q1 2024 and has held it in 9 quarters since. The position peaked at $190K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • KBC Group held 3,064 shares of Crinetics Pharmaceuticals worth $111K as of Q1 2026.
  • KBC Group left its Crinetics Pharmaceuticals share count unchanged in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1260 holding.
  • KBC Group first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • KBC Group's Crinetics Pharmaceuticals position peaked at $190K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.